Acne Medication

AcneMedicationMarketSize,Share,GrowthAnalysis,By TherapeuticClass(Retinoid,TopicalRetinoid&Combination Retinoid),ByFormulation(TopicalMedication,Oral Medication),ByType(PrescriptionMedicine,Over-thecounter(OTC)Medicine),ByAcneType(InflammatoryAcne, Non-inflammatoryAcne),ByDistributionChannel(Retail Store,Pharmacy&DrugStore),ByRegion(NorthAmerica, U.S.)-IndustryForecast2023-2030

Acne Medication Market Insights

MarketOverview:

The rising prevalence of acne-related disorders is expected to propel market growth over the forecast period. Acne, for example, is the most common skin condition in the United States, affecting approximately 50 million people

annually, according to data provided by the American Academy of Dermatology Association in 2021. Furthermore, approximately 85% of people aged12to24haveatleastminoracne.Themarket'sexpandingrobustpipeline of acne medications is expected to drive market growth over the forecast period. For instance, Bausch Health Companies Inc., a global healthcare company, and Ortho Dermatologics, one of the major prescription dermatological health care companies, announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating IDP-126, a combination retinoid, anti-bacterial, and antibiotic topical, to treat acne vulgaris in patients nine years of age and older. IDP-126, if approved, would be the first of its kind to usethistriple combination.

Get more info about Acne Medication- https://www.skyquestt.com/report/acne-medication-market

Analysis:

SegmentationAnalysis:

The Acne Medication Market is segmented by Therapeutic Class, Formulation, Type, Acne Type, Distribution Channel, Region. We are analyzing the market of these segments to identify which segment is thelargest now and in the future, which segment hasthehighest growth rate, and the segment which offersthe opportunity in thefuture.

RegionalAnalysis:

Acne Medication Market is being analyzed by North America, Europe, AsiaPacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro andmacro trends.

RiskAnalysis:

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Acne Medication Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Acne Medication Market's supply chain, distribution, and total revenue growth.

KeyPlayersCoveredintheReport:

• Almirall SA.

• Bausch Health Companies Inc.

• GlaxoSmithKlinePlc (GSK)

• Johnson & Johnson

• Galderma S.A

• Mayne Pharma Group Limited

• Mylan N.V.

• Pfizer Inc.

• Sun Pharmaceutical Industries Limited

• Teva Pharmaceutical Industries Ltd.

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

Acne Medication

Published on Jun 13, 2023

vishvendrasingh.skyquestt

Acne Medication Market Insights Market Overview: The rising prevalence of acne-related disorders is expected to propel market growth over the forecast period. Acne, for example, is the most common skin condition in the United States, affecting approximately 50 million people annually, according to data provided by the American Academy of Dermatology Association in 2021. Furthermore, approximately 85% of people aged 12 to 24 have at least minor acne. The market's expanding robust pipeline of acne medications is expected to drive market growth over the forecast period. For instance, Bausch Health Companies Inc., a global healthcare company, and Ortho Dermatologics, one of the major prescription dermatological health care companies, announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating IDP-126, a combination retinoid, anti-bacterial, and antibiotic topical, to treat acne vulgaris in patients nine years of age and older.